NCT00404586 - Effects Of Single Doses Of GW784568X On Allergic Rhinitis Symptoms In Male Subjects Whilst In An Environmental Chamber | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 11, 2006

Primary Completion Date

January 16, 2007

Study Completion Date

January 16, 2007

Conditions

Rhinitis, Allergic, Perennial

Interventions

DRUG

GW784568X

GW784568X will be delivered as a micronized suspension (50 or 100mcg/spray) via an aqueous nasal spray. Dose planned for treatment groups are 100, 200 and 400 mcg.

DRUG

Fluticasone propionate

Fluticasone propionate will be delivered 50 mcg/spray and planned dose is 200 mcg.

DRUG

Placebo

Matching Placebo to GW784568X as aqueous nasal spray.

Trial Locations (1)

30625

GSK Investigational Site, Hanover